ClinicalTrials.gov record
Completed Phase 2 Interventional

Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia

ClinicalTrials.gov ID: NCT01092065

Public ClinicalTrials.gov record NCT01092065. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 7:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 6-week, Double-blind, Placebo-controlled, Randomized, Multicenter Study to Explore the Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With OFF Time and Moderate-severe L-dopa Induced Dyskinesia

Study identification

NCT ID
NCT01092065
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Novartis
Industry
Enrollment
23 participants

Conditions and interventions

Interventions

  • AFQ056 with L-dopa Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
30 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2010
Primary completion
Jun 30, 2011
Completion
Jun 30, 2011
Last update posted
Dec 22, 2020

2010 – 2011

United States locations

U.S. sites
4
U.S. states
4
U.S. cities
4
Facility City State ZIP Site status
The Parkinsons Institute Sunnyvale California 94085
Colorado Neurological Institute Englewood Colorado 80113
Indiana University School of Medicine Indianapolis Indiana 46202
University of Kansas Medical Center - Parkinson's Disease and Movement Disorders Center Kansas City Kansas 66160

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01092065, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 22, 2020 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01092065 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →